References:
1) Hypertrophic cardiomyopathy: genetics and clinical perspectives. Wolf
CM. Cardiovasc Diagn Ther . 2019;9(Suppl 2):S388‐S415.
doi:10.21037/cdt.2019.02.01
2) 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of
Hypertrophic Cardiomyopathy. A Report of the American College of
Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS
et al.
Circulation. 2011
Dec 13;124(24):2761-96. doi: 10.1161/CIR.0b013e318223e230.
3) Current state of the roles of alcohol septal ablation and surgical
myectomy in the treatment of hypertrophic obstructive
cardiomyopathy. Douglas JS Jr. Cardiovasc Diagn Ther .
2020;10(1):36‐44. doi:10.21037/cdt.2019.07.02
4) Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive
Cardiomyopathy. O’Mahony C, Mohiddin SA, Knight C. Interv
Cardiol . 2014;9(2):108‐114. doi:10.15420/icr.2011.9.2.108